Three Alternative Scenarios of the Future In Vitro Diagnostics Market

• Publication date: January 2012

This report is an invaluable strategic planning resource for corporate, marketing and R&D executives. The report is designed to help executives develop effective contingency plans that best accommodate uncertainties ahead. The study objectives include:To identify and evaluate emerging markets and technologies that may present unexpected threats or offer opportunities. To identify key strategic decisions that will have to be made...

This report is an invaluable strategic planning resource for corporate, marketing and R&D executives. The report is designed to help executives develop effective contingency plans that best accommodate uncertainties ahead. The study objectives include:

• To identify and evaluate emerging markets and technologies that may present unexpected threats or offer opportunities.
• To identify key strategic decisions that will have to be made in the future.
• To enhance corporate ability to develop realistic contingency plans.
• To prepare executives to accommodate radically different operating climates and reduce surprises.
• To challenge accepted perceptions of the future diagnostics market.

- How will the future reimbursement changes affect individual market segments?

- Will the industry consolidate, decentralize, or undergo a bimodal transformation?

- What will be the impact on purchasing influences, marketing strategies, joint ventures, mergers, licensing, import and export?

- How will the future technological advances affect the major market segment?

- Which companies will enter the market and which will not survive?

These and other key issues facing the decision-makers are explored in this thought-provoking and multi-faceted portrait of the three possible futures and their strategic implication. We would be glad to answer any questions you might have regarding this informative, comprehensive and insightful market research and technology assessment report, and look forward to your subscription.

In Vitro Diagnostic Industry

Table of Contents

I. INTRODUCTION
II. EXECUTIVE SUMMARY
A. BUSINESS-AS-USUAL SCENARIO
B. ECONOMIC AUSTERITY SCENARIO
C.TECHNOLOGICAL BREAKTHROUGHS SCENARIO
III. CONCLUSIONS AND RECOMMENDATIONS
IV.THE SCENARIOS, 2006-2016
A. BUSINESS-AS-USUAL SCENARIO
1. Business Environment
a. Health Care Expenditures
b. Cost-Consciousness
c. Reimbursement
d. Industry Consolidation
e. Managed Care
• PPOs
• HMOs
f. Hospitals
g. Admissions
h. Length of Stay
i. Industry Diversification
j. Physician Demographics
k. Aging Population
• Chronic Illnesses
• Disease Incidence
• Susceptibility to Iatrogenesis
• Multiple Illness Cases
l. Laboratory Regulations
m. The FDA Reform
2. Outlook for the In Vitro Diagnostics Market
a. Government Regulations
b. Centralized Testing
• Hospitals
• Commercial Laboratories
• Blood Banks
• Public Health Laboratories
c. Decentralized Testing
• Personal Testing
• Physician Offices/Group Practices
• Ancillary Hospital Locations
- ERs
- ORs
- ICUs/CCUs
• Cancer Clinics
• Ambulatory Care Centers
• Surgery Centers
• Nursing Homes
• Birth Centers
3. Strategic Implications
a. Testing Patterns
• Test Utilization
• Pre-Admission Testing
• Inpatient Testing
• Outpatient Testing
4. Market Segments
a. Chemistry and Immunoassay
• Introduction
• Future Situation
b. Microbiology and Serology
• Introduction
• Future Situation
c. Hematology and Flow Cytometry
• Introduction
• Future Situation
d. Histology and Cytology
• Introduction
• Future Situation
e. Coagulation
• Introduction
• Future Situation
f. Urinalysis
• Introduction
• Future Situation
g. Blood Banking
• Introduction
• Future Situation
5.Technologies
a. Genomics
• Introduction
• Future Situation
b. Proteomics
• Introduction
• Future Situation
c. DNA Probes
• Introduction
• Future Situation
d. Biochips/Microarrays
• Introduction
• Future Situation
e. Monoclonal Antibodies
• Introduction
• Future Situation
f. Solid Phase Chemistry
• Introduction
• Future Situation
g. Biosensors
• Introduction
• Future Situation
h. Automation and Robotics
• Introduction
• Future Situation
i. Computer-Aided Diagnosis
• Introduction
• Future Situation
6.The New Marketplace
a. Purchasing Influences
b. Marketing Strategies
c. Joint Ventures, Mergers and Licensing
d. Import-Export
e. Potential Market Entrants
f. Who May Not Survive?
B. ECONOMIC AUSTERITY SCENARIO
1. Business Environment
a. Socio-Political Climate
• Cost-Consciousness
• Government Actions
• Three-Tier System
• Health Rationing
• Voucher System
• Health IRA
b. Hospital Closures
c. Hospital Utilization
d. Hospital Reorganization
e. Physician Regulations
f. Wellness Programs
g. Corporate Responses
h. Academic Research
2. Outlook for the In Vitro Diagnostics Market
a. Test Utilization
• Ordering Practices
• Documentation
• Recertification
b.Technology Regulations
c. New Laboratory Ventures
d. Computers
e. Industrial Medicine
f. Insurance Companies
g. Test Volume and Market Size
3. Strategic Implications
a. Testing Patterns
• Pre-Admission Testing
• Inpatient Testing
• Outpatient Testing
b. Market Segments
• Chemistry and Immunoassay
• Microbiology and Serology
• Hematology and Flow Cytometry
• Histology and Cytology
• Coagulation
• Urinalysis
• Blood Banking
c.Technologies
• Genomics
• Proteomics
• DNA Probes
• Biochips/Microarrays
• Monoclonal Antibodies and Immunoassays
• Automation and Robotics
• Solid Phase Chemistry
• Biosensors
• Computer-Aided Diagnosis
d.The New Marketplace
• Purchasing Influences
• Marketing Strategies
• Joint Ventures, Mergers and Licensing
• Import-Export
• Potential Market Entrants
• Who May Not Survive?
C.TECHNOLOGICAL BREAKTHROUGHS SCENARIO
1. Business Environment
a. Political/Regulatory Climate
b. R & D Funding
c. Industry-Government Relationship
d. Industry-University Ventures
e.Technological Environment
f. Testing Decentralization
g. Health Care Expenditures
h. Physician Population
i. Hospital Indicators
2. Outlook for the In Vitro Diagnostics Market
a. Overview
b. Genomics
c. Proteomics
d. DNA and RNA Probes
e. Biochips/Microarrays
f. Monoclonal Antibodies
g. Immunoassays
h. Information Technology
i. Laboratory Automation and Robotics
j. Solid Phase Chemistry
k. Biosensors
l. Holography
m. Pharmaceuticals
3. Strategic Implications
a.Testing Patterns
• Pre-Admission Testing
• Inpatient Testing
• Outpatient Testing
• Test Volume and Market Size
b. Market Segments
• Chemistry and Immunoassay
• Microbiology and Serology
• Hematology and Flow Cytometry
• Histology and Cytology
• Coagulation
• Urinalysis
• Blood Banking
c.The New Marketplace
• Purchasing Influences
• Marketing Strategies
• Joint Ventures, Mergers and Licensing
• Import-Export
• Potential Market Entrants
• Who May Not Survive?
V.APPENDICES: METHODOLOGY
A.The Delphi
B. Cross-Impact Analysis
C. Substitution Modeling
Table of ContentsExecutive Summary Table I: Business-As-Usual
Scenario, Growth Areas in Clinical Laboratory
Testing, 2008-2018
Executive Summary Table II: Economic Austerity
Scenario, Growth Areas in Clinical Laboratory
Testing, 2008-2018
Executive Summary Table III: Technological
Breakthroughs Scenario, Growth Areas in
Clinical Laboratory Testing, 2008-2018
Executive Summary Table IV: Market Size by Location
Executive Summary Table V: Market Size by Laboratory
Discipline
Table-1: Business-As-Usual Scenario, Health
Care Costs by Expenditure Type
Table-2: Business-As-Usual Scenario, HMO and PPO
Enrollment
Table-3: Business-As-Usual Scenario, Selected
Hospital Statistics
Table-4: Business-As-Usual Scenario,Total Population
and Physician Demographics
Table-5: Business-As-Usual Scenario,Test Volume
by Location
Table-6: Business-As-Usual Scenario,Test Distribution
by Location
Table-7: Business-As-Usual Scenario, Market Size
by Location
Table-8: Business-As-Usual Scenario,Typical
Pre-Admission Tests
Table-9: Business-As-Usual Scenario,Test Volume
by Laboratory Discipline
Table-10: Business-As-Usual Scenario, Market Size
By Laboratory Discipline
Table-11: Economic Austerity Scenario, Selected
Hospital Statistics
Table-12: Economic Austerity Scenario,
HMO and PPO Enrollment
Table-13: Economic Austerity Scenario,Total Population
and Physician Demographics
Table-14: Economic Austerity Scenario, Major
Categories of Overutilized Tests
Table-15: Economic Austerity Scenario,
Test Volume by Location
Table-16: Economic Austerity Scenario,Test
Distribution by Location
Table-17: Economic Austerity Scenario,
Market Size by Location
Table-18: Economic Austerity Scenario,Timing
Requirements for Selected Laboratory Tests
Table-19: Economic Austerity Scenario,Test Volume
by Laboratory Discipline
Table-20: Economic Austerity Scenario, Market Size
by Laboratory Discipline
Table-21: Technological Breakthroughs Scenario, HMO
and PPO Enrollment
Table-22: Technological Breakthroughs Scenario,Total
Population and Physician Demographics
Table-23: Technological Breakthroughs Scenario,
Selected Hospital Statistics
Table-24: Technological Breakthroughs Scenario,
Test Volume by Location
Table-25: Technological Breakthroughs Scenario,
Test Distribution by Location
Table-26: Technological Breakthroughs Scenario,
Market Size by Location
Table-27: Technological Breakthroughs Scenario,
Test Volume by Laboratory Discipline
Table-28: Technological Breakthroughs Scenario,
Market Size by Laboratory Discipline
List of Tables